Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.
| Website: | www.galectintherapeutics.com |
| Email: | ir@galectintherapeutics.com |
| Main Phone: | +1 678 620-3186 |
| Address: | 4960 Peachtree Industrial Boulevard |
| Address 2: | Suite 240 |
| State: | GA |
| City / Town: | Norcross |
| Country: | USA |
| Postal Code: | 30071 |
| Exchange: | NSC |
| CEO: | Harold H. Shlevin |
| Employees: | 7 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 5.00 | Change $ 0.03 | Change % 0.60 | Tick N/A |
| Bid 4.97 | Bid Size 200.00 | Ask 5.00 | Ask Size 2,800.00 |
| Open 4.97 | High 5.00 | Low 4.85 | Prev Close 4.97 |
| Last Trade | Volume 35,111 | 52 Wk Hi 9.49 | 52 Wk Low 1.88 |
| Market Cap 205.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 41,136,738.00 | EPS (TTM) -0.37 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 48 | 56 |
| Number of Buys | 21 | 27 |
| Number of Sells | 27 | 29 |
| Net Activity | -532054 | -661893 |
| Last 10 Buys | Shares |
|---|---|
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Marc Rubin | 1,000 |
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Theodore H. Zucconi | 1,000 |
| Arthur R. Greenberg | 1,000 |
| Peter G. Traber | 1,000 |
| Kevin D. Freeman | 1,000 |
| Peter G. Traber | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Harold H. Shlevin | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 12 | 12 | 12 | 12 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 8.33 | 8.33 | 8.33 | 8.33 |
| Standard Deviation | 3.51 | 3.51 | 3.51 | 3.51 |
| Date of Most Recent Estimate | 05/31/18 | 05/31/18 | 05/15/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
